image description

News. Other News

Juventas Therapeutics doses first patient in Phase II STOP-HF trial

Juventas Therapeutics
PRNewswire-USNewswire, August 20, 2012
Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial. The 90-patient, placebo-controlled, randomized double-blinded Phase II study is evaluating the safety and efficacy for JVS-100 in patients with late stage heart failure. Dr. Amit Patel, the Director of Clinical Regenerative Medicine at University of Utah Medical Center, treated the patient.

Juventas Therapeutics Raises $22.2 Million Series B Financing

Juventas Therapeutics
PRNewswire, July 16, 2012
Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures

Out of view of patients, docs, Clinic shop allows for tool rehab, new idea development

Cleveland Clinic Medical Device Solutions
Crain’s Cleveland Business, January 9, 2012
Surgeons and other doctors who perform miracles get most of the limelight at the Cleveland Clinic, but in the basement of its main campus, a crew of machinist, fabricators, engineers and researchers does impressive work, too —

Steris Corp. and Philips Healthcare deal add jobs, punch to Northeast Ohio’s biomedical economy

Philips Healthcare, December 20, 2011
With Philips Healthcare and Steris Corp. expecting to add 200 local jobs within a year, state and local leaders see more proof that Northeast Ohio’s medical economy can compete on a national – and sometimes global – stage.

Philips Healthcare to add 100 jobs in Highland Heights; Steris Corp. plans growth in Mentor

Philips Healthcare, December 19, 2011
Two healthcare heavyweights will bring jobs to Northeast Ohio, building up the region’s medical core with help from state incentives.

Stroke diagnosis firm IschemiaCare closes $800K of $1.1M investment

Ischemia Care
MedCity News, September 1, 2011
A company that’s hoping to be the first to commercialize a blood test that can diagnose the cause of stroke has closed $800,000 of an anticipated $1.1 million series B round of investment.

Belgian medical device CRO picks Cleveland for U.S. headquarters

MedCity News, August 29, 2011
A Belgian clinical research organization that focuses on cardiovascular medical devices has established its U.S. headquarters in Cleveland.

Global Cardiovascular Innovation Center